These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Eosinophilia and parotitis occurring early in clozapine treatment. Saguem BN; Bouhlel S; Ben Salem C; Ben Hadj Ali B Int J Clin Pharm; 2015 Dec; 37(6):992-5. PubMed ID: 26373547 [TBL] [Abstract][Full Text] [Related]
9. Drug-induced gynecomastia. Thompson DF; Carter JR Pharmacotherapy; 1993; 13(1):37-45. PubMed ID: 8094898 [TBL] [Abstract][Full Text] [Related]
10. [Clozapine-induced parotitis: a case study]. Gouzien C; Valiamé A; Misdrahi D Encephale; 2014 Feb; 40(1):81-5. PubMed ID: 23809173 [TBL] [Abstract][Full Text] [Related]
11. Withdrawal of oxyphenbutazone: what about phenylbutazone? Biron P CMAJ; 1986 May; 134(10):1119-20. PubMed ID: 3697857 [No Abstract] [Full Text] [Related]
12. Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. Inman WH Br Med J; 1977 Jun; 1(6075):1500-5. PubMed ID: 871632 [TBL] [Abstract][Full Text] [Related]
13. Phenylbutazone, oxyphenbutazone labeling revised. FDA Drug Bull; 1984 Dec; 14(3):23-4. PubMed ID: 6526172 [No Abstract] [Full Text] [Related]
14. Fixed drug eruption to oxyphenbutazone and phenylbutazone. Nayyar KC; Pasricha JS Dermatologica; 1972; 144(4):214-6. PubMed ID: 5076722 [No Abstract] [Full Text] [Related]
15. Contact sensitivity to oxyphenbutazone (Tanderil) and cross-sensitivity to phenylbutazone (Butazolidine). Krook G Contact Dermatitis; 1975 Dec; 1(6):385-6. PubMed ID: 139265 [No Abstract] [Full Text] [Related]